Skip to main content
Top
Published in: Annals of Surgical Oncology 2/2007

01-02-2007

Selective Application of Axillary Node Dissection in Elderly Women with Early Breast Cancer

Authors: Dalal Aziz, MD, Sandra Gardner, MMath, Kathleen Pritchard, MD, Lawrence Paszat, MD, MPH, Claire M. B. Holloway, MD, PhD

Published in: Annals of Surgical Oncology | Issue 2/2007

Login to get access

Abstract

Background

Routine use of axillary lymph node dissection (ALND) has been questioned in elderly women. This study examines whether selective application of ALND in early stage breast cancer affects breast cancer-related survival.

Methods

From the Surveillance, Epidemiology, and End Results (SEER) database, records of women ≥70 years of age with stage I or II breast cancer diagnosed between 1990 and 1995 were reviewed. Hazard ratios (HR) of cause-specific survival (CSS) between women receiving ALND and those who did not were compared. To minimize the potential for bias in the selection of women to receive ALND, HR of CSS was compared within propensity analysis deciles.

Results

20,151 women entered the analysis. Median follow up was 6 years (interquartile range 4.33–7.67 years). Seventy-five percent underwent ALND. Women with higher risk disease and younger age were more likely to undergo ALND. Five year unadjusted CSS in women who did and did not receive ALND was 92.1% and 90.6%, respectively, with a HR of 0.85, P = 0.002. Using the propensity analysis method, the adjusted HR for CSS associated with ALND was 0.89, P = 0.066.

Discussion

After adjusting for differences in the probability of receiving ALND, no clinically or statistically significant difference in survival was observed among women who received ALND when compared with those who did not, although we could not account for differences in co-morbidity or use of systemic therapy between groups.

Conclusion

Surgeons select elderly women with early stage breast cancer for ALND with a negligible impact on CSS.
Literature
1.
go back to reference Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347:567–75PubMedCrossRef Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347:567–75PubMedCrossRef
2.
go back to reference Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival—a Bayesian meta-analysis. Ann Surg Oncol 1999; 6:109–16PubMedCrossRef Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival—a Bayesian meta-analysis. Ann Surg Oncol 1999; 6:109–16PubMedCrossRef
3.
go back to reference Chua B, Ung O, Taylor R, Boyages J. Is there a role for axillary dissection for patients with operable breast cancer in this era of conservatism? ANZ J Surg 2002; 72:786–92PubMedCrossRef Chua B, Ung O, Taylor R, Boyages J. Is there a role for axillary dissection for patients with operable breast cancer in this era of conservatism? ANZ J Surg 2002; 72:786–92PubMedCrossRef
4.
go back to reference Roses DF, Brooks AD, Harris MN, Shapiro RL, Mitnick J. Complications of level I and II axillary dissection in the treatment of carcinoma of the breast. Ann Surg 1999; 230:194–201PubMedCrossRef Roses DF, Brooks AD, Harris MN, Shapiro RL, Mitnick J. Complications of level I and II axillary dissection in the treatment of carcinoma of the breast. Ann Surg 1999; 230:194–201PubMedCrossRef
5.
go back to reference Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer 1994; 73:664–7 Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer 1994; 73:664–7
6.
go back to reference Mincey BA, Bammer T, Atkinson EJ, Perez EA. Role of axillary node dissection in patients with T1a and T1b breast cancer: Mayo Clinic experience. Arch Surg 2001(July); 136:779–82 Mincey BA, Bammer T, Atkinson EJ, Perez EA. Role of axillary node dissection in patients with T1a and T1b breast cancer: Mayo Clinic experience. Arch Surg 2001(July); 136:779–82
7.
go back to reference Bourez R, Rutgers E, Van De Velde C. Will we need lymph node dissection at all in the future? Clin Breast Cancer 2002; 3:315–22PubMedCrossRef Bourez R, Rutgers E, Van De Velde C. Will we need lymph node dissection at all in the future? Clin Breast Cancer 2002; 3:315–22PubMedCrossRef
8.
go back to reference Bohler F, Eiter H, Rhomberg W. Is axillary dissection in clinically lymph node-negative breast carcinoma further indicated? Strahlenther Onkol 1998; 174:605–12PubMedCrossRef Bohler F, Eiter H, Rhomberg W. Is axillary dissection in clinically lymph node-negative breast carcinoma further indicated? Strahlenther Onkol 1998; 174:605–12PubMedCrossRef
9.
go back to reference Buchholz TA, Strom EA, McNeese MD, Hunt KK. Radiation therapy as an adjuvant treatment after sentinel lymph node surgery for breast cancer. Surg Clin N Am 2003; 83:911–30PubMedCrossRef Buchholz TA, Strom EA, McNeese MD, Hunt KK. Radiation therapy as an adjuvant treatment after sentinel lymph node surgery for breast cancer. Surg Clin N Am 2003; 83:911–30PubMedCrossRef
10.
go back to reference Reed DR, Lindsley SK, Mann GN, Austin-Seymour M, Korssjoen T, Anderson BO, Moe R. Axillary lymph node dose with tangential breast irradiation. Int J Radiat Oncol Biol Phys 2005; 61:358–64PubMed Reed DR, Lindsley SK, Mann GN, Austin-Seymour M, Korssjoen T, Anderson BO, Moe R. Axillary lymph node dose with tangential breast irradiation. Int J Radiat Oncol Biol Phys 2005; 61:358–64PubMed
11.
go back to reference Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, Boccardo F, et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996; 347:1066–71PubMedCrossRef Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, Boccardo F, et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996; 347:1066–71PubMedCrossRef
12.
13.
go back to reference Coen JJ, Taghian AG, Kachnic LA, Assaad SI, Powell SN. Risk of arm lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys 2003; 55:1209–15PubMed Coen JJ, Taghian AG, Kachnic LA, Assaad SI, Powell SN. Risk of arm lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys 2003; 55:1209–15PubMed
14.
go back to reference Chua B, Ung O, Boyages J. Competing considerations in regional nodal treatment for early breast cancer. Breast J 2002; 8:15–22PubMedCrossRef Chua B, Ung O, Boyages J. Competing considerations in regional nodal treatment for early breast cancer. Breast J 2002; 8:15–22PubMedCrossRef
15.
go back to reference Truong PT, Bernstein V, Wai E, Chua B, Speers C, Olivotto IA. Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1-ST2 breast cancer. Clin Invest 2002; 54:794–803 Truong PT, Bernstein V, Wai E, Chua B, Speers C, Olivotto IA. Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1-ST2 breast cancer. Clin Invest 2002; 54:794–803
16.
go back to reference Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061–7PubMedCrossRef Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061–7PubMedCrossRef
17.
go back to reference Feigelson BJ, Acosta JA, Feigelson HS, Findley A, Saunders EL. T1 breast carcinoma in women 70 years of age and older may not require axillary node dissection. Am J Surg 1996; 172:487–90PubMedCrossRef Feigelson BJ, Acosta JA, Feigelson HS, Findley A, Saunders EL. T1 breast carcinoma in women 70 years of age and older may not require axillary node dissection. Am J Surg 1996; 172:487–90PubMedCrossRef
18.
go back to reference Rosenbaum PR, Rubin DR. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79:516–24CrossRef Rosenbaum PR, Rubin DR. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79:516–24CrossRef
19.
go back to reference Breast Cancer Versus Mastectomy. US General Accounting Office-Program Evaluation and Methodology Division Report #GAO/PEMB-95-9 Breast Cancer Versus Mastectomy. US General Accounting Office-Program Evaluation and Methodology Division Report #GAO/PEMB-95-9
20.
go back to reference Snedecor GW, Cochran WG. Statistical Methods. Seventh Edition. The Iowa State University Press, Ames, Iowa 1980 Snedecor GW, Cochran WG. Statistical Methods. Seventh Edition. The Iowa State University Press, Ames, Iowa 1980
21.
go back to reference Du X, Goodwin JS. Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer 2001; 92:730–7PubMedCrossRef Du X, Goodwin JS. Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer 2001; 92:730–7PubMedCrossRef
22.
go back to reference Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999. J Natl Cancer Inst 2002; 94:1626–34PubMed Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999. J Natl Cancer Inst 2002; 94:1626–34PubMed
23.
go back to reference Chua B, Ung O, Taylor R, Boyages J. Is information from axillary dissection relevant to patients with clinically node-negative breast cancer? Breast J 2003; 9:478–84PubMedCrossRef Chua B, Ung O, Taylor R, Boyages J. Is information from axillary dissection relevant to patients with clinically node-negative breast cancer? Breast J 2003; 9:478–84PubMedCrossRef
24.
go back to reference Di Fronzo LA, Hansen NM, Stern SL, Brennan MB, Giuliano AE. Does sentinel lymphadenectomy improve staging and alter therapy in elderly women with breast cancer? Ann Surg Oncol 2000; 7:406–10CrossRef Di Fronzo LA, Hansen NM, Stern SL, Brennan MB, Giuliano AE. Does sentinel lymphadenectomy improve staging and alter therapy in elderly women with breast cancer? Ann Surg Oncol 2000; 7:406–10CrossRef
Metadata
Title
Selective Application of Axillary Node Dissection in Elderly Women with Early Breast Cancer
Authors
Dalal Aziz, MD
Sandra Gardner, MMath
Kathleen Pritchard, MD
Lawrence Paszat, MD, MPH
Claire M. B. Holloway, MD, PhD
Publication date
01-02-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 2/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9092-y

Other articles of this Issue 2/2007

Annals of Surgical Oncology 2/2007 Go to the issue